49 results about "Bacterial isolate" patented technology

The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: Clostridium-like species, Prevotella-like species, Bacteroides-like species, Enterococcus-like species, Selenomonas species, non-dextran slime producing Streptococcus species and non-slime producing lactic acid bacterial isolates.

Described herein are a plurality of primers which may be used in a multiplex PCR assay in a fast, accurate, reliable and specific fashion for detecting the presence of specific Campylobacter strains within a sample. These kits can be used on bacterial isolates and has the potential for use directly on foods and environmental samples.

The subject invention provides compositions for alleviating type 1 diabetes (T1D). In preferred embodiments, the compositions comprise an effective amount of one or more antigen presenting cells (APCs) that have been pulsed with one or more bacterial isolates and/or compounds from the isolates. The bacteria used to pulse the APCs are, preferably, those that confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. In specific embodiments, these bacteria may be, for example, Eubacteria or Clostridia. In a preferred embodiment, the APCs are dendritic cells (DCs).

Biofungicidal composition from a biologically pure culture of a Chilean bacterial isolate obtained from soils of the seventh region of Maule, Chile, corresponding to Paenibacillus polymyxa SCHC33, strain with the deposit number RGM2141 granted by the depository authority of the Chilean Collection of Microbial Genetic Resources (CChRGM) to be used as an environmentally friendly, biological control agent against fungal plant diseases, particularly fruits susceptible to infection by Botrytis cinerea, efficiently inhibiting conidial germination and mycelium proliferation of said phytopathogenic fungus, furthermore protects plant leaves and fruits from infection by the same fungus, and has the potential to be used in biological control of other fungi and in general of phytopathogenic microorganisms.

A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.

The invention discloses a bacterial isolates relative to suppression of a biofilm and detoxification. The bacterial isolates relative to suppression of the biofilm and detoxification, which is provided by the invention, is especially Proteus mirabilis (Proteus mirabilis)10#, wherein the preservation number of Proteus mirabilis10# in China General Microbiological Culture Collection Center is CGMCC No.6426. The Proteus mirabilis10# CGMCC No.6426, which is provided by the invention, has effects of inhibiting formation of the pathogenic bacteria biofilm and detoxifying. The invention has the following advantages that: (1) through active ingredients (metabolites) of a Proteus mirabilis10# CGMCC No.6426 preparation, growth of the pathogenic bacteria is not influenced, the force is not generated, and the tolerance probability is low; and (2) through active ingredients (metabolites) of a Proteus mirabilis10# CGMCC No.6426 preparation, formation of the pathogenic bacteria biofilm is inhibited and the toxicity of the pathogenic bacteria is reduced.

The present invention relates to an environment friendly, safe, and efficient four-step method of bio-bleaching Kraft pulp using bacterial strains of accession no. MTCC 5096, MTCC 5094, MTCC 5095, and MTCC 5098, a microbial consortium comprising a synergistic mixture of ligninolytic bacterial isolates of accession no. MTCC 5094, MTCC 5095, and MTCC 5098, bacterial strains of accession Nos. MTCC 5096, MTCC 5094, MTCC 5095, and MTCC 5098, and a process of preparing an inoculum of the bacterial isolate of accession no. MTCC 5096, further, a process for the preparation of a consortium comprising the ligninolytic bacterial isolates of accession nos. MTCC 5094, MTCC 5095, and MTCC 5098, in addition, a process for the preparation of pulp suspension for the bio-bleaching.

A biodegradation process for the organophosphonate product of Sarin (O-isopropyl methylphosphonofluoridate) hydrolysis, i.e., isopropylmethylphosphonate (IMPA). This process provides a feasible biodegradation demilitarization alternative to Sarin incineration. Public opposition of nerve agent incineration is widespread, and alternative methods are sought to help the U.S. Army meet the 2007 demilitarization deadline imposed by the Chemical Weapons Convention. This process uses a two-step approach to IMPA biodegradation. In the first step, a concentrated IMPA solution is used as the sole nutritional carbon and phosphorus source for microbial cultures. The second step involves diluting the culture and adding an inexpensive carbon source to encourage bacterial phosphate assimilation. The biodegradation typically involves a consortium of microorganisms comprising Methylobacterium radiotolerans GB21, Agrobacterium tumefaciens GB2GA, Klebsiella oxytoca GB2CS, GB272, Aureobacterium sp. GB2 and three bacterial isolates belonging to the same species GB23, GB272, and GB292.

The invention provides a bacterial isolate defined by accession number 180507-1 filed with the International Depository Authority of Canada. The bacteria are capable of degrading trichothecene mycotoxins. Also provided are compositions comprising the bacteria and methods of preventing or treating food, foodstuffs, crops and harvested crops that are contaminated or susceptible to contamination with trichothecene mycotoxins. Kits are also provided.

A single kit comprising 3 multiplex PCR assays that can detect in E. coli the presence of the 8 virulence genes: eaeA, EHEC-HlyA, Stx1 (VT1), Stx2 (VT2), Stx2c (VT2c), Stx2d (VT2d), Stx2e (VT2e) and Stx2f (VT2f) is described. In addition, the kit can detect the two critical serotypes (O157 and H7) and identify the species (Escherichia coli) simultaneously using a one step reaction. Following evaluation in our hands, this PCR kit has been used to detect the above 11 components of disease-causing E. coli in a fast, accurate, reliable and specific fashion. These kits can be used on bacterial isolates and has the potential for use directly on foods and environmental samples.

The invention provides a culture method for improving yield and viscosity of bacterial polysaccharides. By using the characteristic that penbritin can be simultaneously used as a mutagenic agent and bacterial cell wall peptidoglycan to synthesize stress factors, the penbritin is added to subsequent subculture processes of bacterial isolates for producing different polysaccharides; the adding amount of the penbritin is gradually increased along with an increase of passage number, so as to improve thrill on bacterial cells; and a series of high-producing strains with different viscosities and improvement degrees can be screened in the continuous passage process, so as to adapt to different application requirements. Therefore, the production cost is reduced.

Disclosed herein are marine bacterial substances, methods, and medical devices that inhibit biofilm growth and/or formation. Substances of the present disclosure are products or byproducts of P3-2 (ATCC PTA-6763), P4-4 (ATCC PTA-6682), P5-2 (ATCC PTA-6764), or P6-6 (ATCC PTA-6766) marine bacterial isolates.

A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.

The present invention provides systems and methods for surveillance, diagnosis, and evaluation of high risk bacterial transmission events. The systems and methods utilize software and computational systems that automate identification, surveillance, and communication. The invention further includes archival systems for use in the systems and methods that compile bacterial isolates linked to information about patients, pre-operative, intra-operative, or post-operative arenas, healthcare providers, and the like.

Described herein are compositions and methods for delivering microbial therapeutic agents useful for the treatment of conditions associated with dysbacteriosis of intestinal flora. In various aspects, the present invention provides compositions and methods useful for treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof. For example, the present invention relates, in part, to a plurality of bacterial isolates wherein at least two of the plurality of bacterial isolates are isolated from faeces of different human donors.

Described herein are compositions and methods for delivering microbial therapeutic agents useful for the treatment of conditions associated with dysbacteriosis of intestinal flora. Described herein are compositions and methods for protecting the gastrointestinal microbiome in a subject. In various embodiments, provided herein are pharmaceutical compositions comprising isolated or purified bacterial isolates and/or mixtures of isolated or purified bacterial isolates (e.g., faeces from humans, e.g., from healthy humans).